The long-term goal of MX-MAP is to develop a functional pipeline for the immune characterization of new 2D nanomaterials of MXene family, for the qualitative and quantitative assessment of the human immune compatibility and immune activity towards biomedical applications. The immune characterization of the tested materials on the basis of intrinsic physical-chemical and immunological properties, through the combination of the most innovative technologies such as single-cell mass cytometry (CyTOF), will open breakthrough perspectives for the development of new therapeutic approaches applying nanomaterials as immunomodulators, scaffolds for tissue engineering, cancer therapy, and antibacterial agents. MX-MAP will develop key chemistry and immune-based strategies for MXene medical applications. The implication of this project extends beyond the specific nanoscience program greatly advancing the engineering process of 2D materials and their use in biomedicine. The MX-MAP project involves fourteen key players in European and non-European countries, including the United States, Canada, Saudi Arabia, and three partners from Ukraine, coming from academia and SMEs. This program will provide strong support for the development of the careers of young brilliant scientists who want to grow towards an interdisciplinary vision of Science. Chemistry, biology, immunology, engineering, and cancer research are the expertise of MX-MAP. The senior team members are among the most influential scientists, including Prof. Yury Gogotsi (H-index=168) - inventor of MXenes, Prof. Klaus Ley (H-index=147) - one of the most cited immunologists worldwide, and Prof. Husam N Alshareef (H-index=99). The Consortium is perfectly balanced in terms of equal gender presence; the project Coordinator Lucia Gemma Delogu is a female, and 2 out 4 of four WP leaders are female. The project embraces a large view of inclusiveness and diversity, including countries with smaller economies such as Ukraine.

There are three main reasons for an immediate innovation action to apply big data technologies in Healthcare. Firstly, a Healthy nation is a Wealthy nation! An improvement in health leads to economic growth through long-term gains in human and physical capital, which ultimately raises productivity and per capita GDP. Secondly, Healthcare is one of the most expensive sectors, which accounts for 10% of the EU’s GDP continuously becoming more expensive. Thirdly, as healthcare is traditionally very conservative with adopting ICT, while big healthcare data is becoming available, the expected impact of applying big data technologies in Healthcare is enormous. BigMedilytics will transform Europe’s Healthcare sector by using state-of-the-art Big Data technologies to achieve breakthrough productivity in the sector by reducing cost, improving patient outcomes and delivering better access to healthcare facilities simultaneously, covering the entire Healthcare Continuum – from Prevention to Diagnosis, Treatment and Home Care throughout Europe. BigMedilytics produces: • A Big Data Healthcare Analytics Blueprint (defining platforms and components), which enables data integration and innovation spanning all the key players across the Healthcare Data Value Chains • Instantiations of the Blueprint which implement BigMedilytics concepts across 12 large-scale pilots accounting for an estimated 86% of deaths and 77% of the disease burden in Europe • The Best “Big Data technology and Healthcare policy” Practices related to big data technologies, new business models and European and national healthcare data policies and regulations. BigMedilytics will maximize the impact by using its Big Data Healthcare Analytics Blueprint and the Best Practices to scale-up the concepts demonstrated in the 12 pilots, to the whole Healthcare sector in Europe. It will use health records of more than 11 million patients across 8 countries and data from other sectors such as insurance and public sector.

Approximately 45-60% of all cancer patients are treated with radiotherapy. Some of these patients have a good outcome, but in other cases their illness fails to be cured. This may result from distant metastases or from regrowth of the primary tumor. This training network is built on the premise that considerable advances in understanding radiobiology will open novel routes for effective therapeutic intervention with biological targets to improve the outcome of cancer treatment; this progress requires a European-wide effort. This network of radiobiologists, clinicians and scientists with complementary expertise will stimulate outstanding science, meeting the high demand for excellent young academics enhancing Europe´s competitive capability in this highly relevant but underrepresented and fragmented research area. We will strengthen collaborations and technological platforms to develop effective therapeutic strategies for cancer. The failure to eliminate the primary cancer can be placed into 2 categories: the radioresistance of the tumor and the sensitivity of surrounding normal tissue; and the effects of the tumor microenvironment leading to greater overall resistance and altering the immune response to the tumor. This will be combined with translational work designed to identify and implement new therapeutic strategies for use in radiotherapy. Students will benefit from the expertise of the whole, both academic and industrial including unique research technologies that will now be available throughout the network, including a variety of screening platforms, methodology for preclinical cancer therapy and novel radiation and imaging technologies. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combating a major death-related disease in Europe this project will raise health and bring long-term benefit to the European and international community.

As emerging technologies are transforming the way we approach medical and healthcare education, it is imperative that our trainees are at the forefront of the development of new tools and digital platforms, while simultaneously becoming fluent in these technologies. In the INSIDE:INSIGHT project, we build a training network for young professionals, making them versed in educational technologies, 3D visualisation and collaborative working, while equipping them with a wide range of transferable skills. This is attained by bringing together researchers from biomedical sciences, computer sciences, educational sciences, biomedical engineering, medical technology and bioethics, as well as partners from the industry. The research focuses on the development, implementation and validation of XR-enhanced educational tools for biomedical and health sciences. This is achieved by: 1) Developing evidence-based technology-enhanced learning (TEL) materials and platforms building upon our track record in this domain; 2) Using a theoretical framework to evaluate how the implementation of TEL materials impacts effective learning and knowledge retention, and 3) To identify the elements that are needed to maximize these effects. By integrating disciplines and sectors we go beyond the state-of-the-art and develop evidence-based XR learning environments that are effective, future-proof and tailored to the needs of diverse learners. The project addresses EU's Open Education policy, creating learning materials that are free and accessible to all, at any time. This will facilitate remote learning taking student diversity in all its aspects into account. At the same time, this interdisciplinary and intersectoral network creates diverse, high-level training opportunities for the proposed Doctoral Candidates providing the trainees with a broad range of skills that will empower them to become the leaders of tomorrow.